Spreadsheet: 04ccdaaf-8b06-41c3-a52b-189040dff6f6
Sheet: 2. Instructions

 | General instructions for using this costing tool
 | 1) Enter data/unit costs in BLUE cells only  2) Unit cost for ARVs and laboratory tests for each country are available from  http://www.who.int/hiv/amds/gprm/en/index.html (WHO Global price reporting mechanism) 3) Unit cost for health services for each country are available from [NAME] (Choosing interventions that are cost effective WHO-CHOICE) 4) Costs are in USD  Please contact Dr. [NAME] at [EMAIL] for further information
 | Items | Input
 | Scenario | Enter scenario description (e.g. 90% HIV testing coverage 90% PMTCT coverage)
 | Estimated number of births | Estimated number of births per year (or per defined period) per target population
 | HIV prevalence among pregnant women (%) | Prevalence among pregnant women (including women diagnosed and on ART previous to pregnancy) or, if not available, adult (15-49) prevalence
 | ANC attendance (%) | Percentage of women who accessed antenatal care (at least 4 visits, first visit before week 14)
 | Percentage of pregnant women who had the HIV test (%) | Coverage of HIV testing among pregnant women who accessed ANC   * for 'current scenario without ANC data', enter coverage of HIV testing regardless ANC attendance
 | Percentage of pregnant women tested HIV positive who received ARVs (%) | Coverage of ARV prophylaxis/ART among HIV positive pregnant women who accessed antenatal care and received HIV test * for 'current scenario without ANC data', enter coverage of ARV prophylaxis regardless ANC attendance and HIV testing
 | Pregnant women with HIV diagnosis previous to current pregnancy who receive ART (%) | Percentage of pregnant women with HIV diagnosis previous to pregnancy who are receiving ART. It is assumed that these women attended ANC and PMTCT services
 | ART | This tool will only consider "on treatment" those pregnant women who receive 3 ARV drugs. If the country still uses monotherapy or bitherapy, those cases must be considered as "not treated" and, therefore, should  be subtracted from the percentage of pregnant women covered with ART.
 | Breastfeeding among general population (average in months) | Average duration (in months) of breastfeeding among general population
 | PMTCT
 | HIV screening at ANC
 | Unit cost of HIV test (screening) | Cost of HIV screening test per case
 | Unit cost of HIV test (confirmation) | Cost of HIV confirmatory test per case
 | Unit cost of counselling for HIV positive pregnant women | Cost of post-test counselling per positive case (*VCT services average $16 per client15)
 | Unit cost of CD4 test | Cost of CD4 test per case
 | Unit cost of viral load | Cost of viral load per case
 | ARV prophylaxis for pregnant women and exposed infants
 | Unit cost of ARVs
 | ABC 300mg | Cost of each drug (per tablet or ml)    Unit cost for ARVs and laboratory tests for each country are available from  http://www.who.int/hiv/amds/gprm/en/index.html (WHO Global price reporting mechanism)  Costs included by default are PAHO Strategic Fund prices
 | AZT 10mg/ml
 | AZT 300mg
 | AZT 300mg/3TC 150mg
 | AZT 300mg/3TC 150mg/NVP 200mg
 | EFV 600mg
 | LPV/r 200mg/50mg
 | NVP 10mg/ml
 | TDF [NAME]EFV 600mg
 | TDF 300mg/FTC 200mg/EFV 600mg
 | Drug wastage (%)
 | Tablets | Expected wastage of drug. If data are not available either enter 0 or keep default wastage rates (5% for tablets and 20% for syrups)
 | Syrups
 | 1) Pregnant women who are eligible for ART for their own health
 | Percentage of HIV positive pregnant women who are eligible for ART or already on ART (%) | Enter the percentage based on available data in the country, otherwise keep 40% as default
 | Percentage of ART eligible women who are on AZT+3TC+NVP (%) | Among women who are eligible for ART, percentage of women who initiate AZT+3TC+NVP
 | Replacement feeding
 | Weight of formula per tin (g) | Weight of formula per tin (in grams)
 | Unit cost of formula per tin | Cost of formula per tin
 | Volume of formula per 50ml of water (g) | Volume of formula to mix with 50ml of water (in grams)
 | Length of replacement feeding (0, 6, 12, 18 months) | Period of formula milk provision for children of HIV-infected mothers
 | Other costs for PMTCT
 | Percentage of HIV positive pregnant women who deliver by cesarean section | Women with HIV diagnosis who deliver by cesarean section (%)
 | Cost of cesarean section (including AZT iv) | Cost (in USD) of performing a cesarean section to HIV positive women, including the cost of AZT iv
 | Cost of vaginal birth (including AZT iv) | Cost (in USD) of performing a vaginal birth to HIV positive women, including the cost of AZT iv
 | Cost of co-trimoxazole prophylaxis up to 18 months (per exposed infant) | Cost of co-trimoxazole prophylaxis per infant If data is not available enter $14.216 per infant
 | Unit cost of HIV virological test (PCR) for exposed children | Cost of HIV PCR per case
 | Unit cost of HIV serological test for exposed children | Cost of (serological) HIV test per case
 | Unit cost of counselling for caregivers of HIV positive children | Cost of post-test counselling for caregivers per positive case (*VCT services average $16 per client15)
 | Cost of health service (PMTCT follow up) per visit | Unit cost for health services for each country are available from [NAME] (Choosing interventions that are cost effective WHO-CHOICE)
 | Total number of visits (14weeks of pregnancy till 18 months after birth) | Total number of visits to health facilities required from during pregnancy until 18 months after birth
 | Prevention of congenital syphilis
 | [NAME] among pregnant women (%) | Prevalence among pregnant women or, if not available, adult prevalence (15-49)
 | Percentage of pregnant women who had syphilis test (%) | Coverage of syphilis test among pregnant women who accessed ANC  * for 'current scenario without ANC data', enter testing coverage regardless ANC attendance
 | Percentage of pregnant women with maternal syphilis who received treatment by 24 weeks of pregnancy (%) | Coverage of maternal syphilis treatment among pregnant women who accessed antenatal care and received syphilis test   * for 'current scenario without ANC data', enter coverage of treatment for women who were tested and found seropositive regardless ANC attendance
 | Unit cost of syphilis test (screening) | Cost of a syphilis screening test per case
 | Unit cost of benzylpenicillin/2.4million unit | Cost of benzylpenicillin (2.4million unit)
 | Unit cost of benzylpenicillin/150,000 unit (exposed infants) | Cost of benzylpenicillin (150,000 unit)  Body weight of baby is assumed as 3kg
 | Unit cost of syphilis test (diagnosis for infants) | Cost of a syphilis test for diagnosis of infection in infants
 | Treatment for paediatric HIV infection
 | Unit cost of ARVs
 | AZT 60mg/3TC 30mg/NVP 50mg | Cost of each drug (per tablet or ml)  Unit cost for ARVs and laboratory tests for each country are available from  http://www.who.int/hiv/amds/gprm/en/index.html (WHO Global price reporting mechanism) The costs included by default in this tool are PAHO Strategic Fund prices
 | AZT 300mg/3TC 150mg/NVP 200mg
 | AZT 60mg/3TC 30mg
 | AZT 300mg/3TC 150mg
 | LPV/r 80mg/20mg
 | LPV/r 100 mg/25 mg
 | EFV 200mg
 | Drug wastage (%)
 | Tablets | Expected wastage of drug
 | Syrups | If data are not available either enter 0 or keep default wastage rates (5% for tablets and 20% for syrups)
 | Children whose mothers accessed PMTCT services
 | 2) Treatment for children without prior exposure to NVP | Please select 1 or 2 in the box below
 | Selected regimen 1. AZT+3TC+NVP 2. AZT+3TC+LPV/r
 | Children whose mothers did not access PMTCT services | Please select 1, 2 or 3 in the box below
 | Selected regimen 1. AZT+3TC+NVP 2. AZT+3TC+EFV 3. AZT+3TC+LPV/r
 | Other costs related to paediatric HIV treatment
 | Cost of co-trimoxazole prophylaxis for 5 years per child | Cost of co-trimoxazole prophylaxis for 5 years If data is not available enter $5016
 | Cost of health service (out-patient visit) per visit | Unit cost for health services for each country are available from [NAME] (Choosing interventions that are cost effective WHO-CHOICE)
 | Number of visits per year per child | Required number of the visit to health facilities per year per child
 | Cost of laboratory monitoring per year per child | Cost of laboratory monitoring per year for continuing case If data is not available enter $19015
 | Children on 2nd line regimen
 | Rate of treatment failure (switch to 2nd line regimen) per year (%) | Enter available data from the country
 | Cost difference between 1st and 2nd line regimen (per person per year) | (annual cost of selected 1st line regimen) - (annual cost of mostly used 2nd line regimen) * It is assumed that 2nd line regimen is: ABC+3TC+LPV/r